 [1m([0morchestrator-bleeding-LISINOPRIL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes LISINOPRIL increase or decrease the risk of bleeding?[0m
 [1m([0morchestrator-bleeding-LISINOPRIL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-bleeding-LISINOPRIL[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-bleeding-LISINOPRIL[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does LISINOPRIL increase or decrease the risk of bleeding?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-bleeding-LISINOPRIL[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes LISINOPRIL increase or decrease the risk of bleeding?[0m
 [1m([0morchestrator-bleeding-LISINOPRIL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-bleeding-LISINOPRIL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-bleeding-LISINOPRIL[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes LISINOPRIL increase or decrease the risk of bleeding?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does LISINOPRIL increase or decrease the risk of bleeding?"[0m[32m,[0m
[32m    [0m[32m"filter_drugs"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"LISINOPRIL"[0m
[32m    [0m[1;32m][0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: LISINOPRIL: indications_and_usage: INDICATIONS AND USAGE Lisinopril and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood [0m
[31mpressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a[0m
[31mwide variety of pharmacologic classes including lisinopril and hydrochlorothiazide. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as [0m
[31mappropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than [0m[1;31m1[0m[31m drug to achieve blood pressure [0m
[31mgoals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Programâ€™s Joint National Committee on Prevention, Detection, [0m
[31mEvaluation, and Treatment of High Blood Pressure [0m[1;31m([0m[31mJNC[0m[1;31m)[0m[31m. LISINOPRIL: indications_and_usage: Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of [0m
[31maction, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic [0m
[31mproperty of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in [0m
[31mmyocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg [0m
[31mis greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. LISINOPRIL: indications_and_usage: Relative risk reduction from blood [0m
[31mpressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension [0m[1;31m([0m[31mfor example, [0m
[31mpatients with diabetes or hyperlipidemia[0m[1;31m)[0m[31m, and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood [0m
[31mpressure effects [0m[1;31m([0m[31mas monotherapy[0m[1;31m)[0m[31m in black patients, and many antihypertensive drugs have additional approved indications and effects [0m[1;31m([0m[31me.g., on angina, heart failure, or diabetic kidney disease[0m[1;31m)[0m[31m. [0m
[31mThese considerations may guide selection of therapy. These fixed-dose combinations are not indicated for initial therapy [0m[1;31m([0m[31msee DOSAGE AND ADMINISTRATION [0m[1;31m)[0m[31m. LISINOPRIL: indications_and_usage: In using [0m
[31mlisinopril and hydrochlorothiazide tablets, consideration should be given to the fact that an angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients [0m
[31mwith renal impairment or collagen vascular disease, and that available data are insufficient to show that lisinopril does not have a similar risk. [0m[1;31m([0m[31mSee WARNINGS .[0m[1;31m)[0m[31m In considering use of lisinopril and[0m
[31mhydrochlorothiazide tablets, it should be noted that Black patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to non-Black. [0m[1;31m([0m[31mSee WARNINGS, Head and [0m
[31mNeck Angioedema .         [0m
[31mSOURCE:LISINOPRIL label[0m


[31mCONTENT: LISINOPRIL: pharmacodynamics: Pharmacodynamics Administration of lisinopril to patients with hypertension results in a reduction of supine and standing blood pressure to about the same extent[0m
[31mwith no compensatory tachycardia. Symptomatic postural hypotension is usually not observed although it can occur and should be anticipated in volume and/or salt-depleted patients. [0m[1;31m([0m[31mSee WARNINGS .[0m[1;31m)[0m[31m In [0m
[31mmost patients studied, onset of antihypertensive activity was seen at one hour after oral administration of an individual dose of lisinopril, with peak reduction of blood pressure achieved by six [0m
[31mhours. In some patients achievement of optimal blood pressure reduction may require two to four weeks of therapy. At recommended single daily doses, antihypertensive effects have been maintained for [0m
[31mat least [0m[1;31m24[0m[31m hours, after dosing, although the effect at [0m[1;31m24[0m[31m hours was substantially smaller than the effect six hours after dosing. The antihypertensive effects of lisinopril have continued during [0m
[31mlong-term therapy. LISINOPRIL: pharmacodynamics: Abrupt withdrawal of lisinopril has not been associated with a rapid increase in blood pressure; nor with a significant overshoot of pretreatment blood[0m
[31mpressure. In hemodynamic studies in patients with essential hypertension, blood pressure reduction was accompanied by a reduction in peripheral arterial resistance with little or no change in cardiac [0m
[31moutput and in heart rate. In a study in nine hypertensive patients, following administration of lisinopril, there was an increase in mean renal blood flow that was not significant. Data from several [0m
[31msmall studies are inconsistent with respect to the effect of lisinopril on glomerular filtration rate in hypertensive patients with normal renal function, but suggest that changes, if any, are not [0m
[31mlarge. In patients with renovascular hypertension lisinopril has been shown to be well tolerated and effective in controlling blood pressure [0m[1;31m([0m[31msee PRECAUTIONS [0m[1;31m)[0m[31m.         [0m
[31mSOURCE:LISINOPRIL label[0m


[31mCONTENT: LISINOPRIL: clinical_pharmacology: [0m[1;31m1[0m[31m mEq/L; however, approximately [0m[1;31m15[0m[31m percent of patients had increases greater than [0m[1;31m0.5[0m[31m mEq/L and approximately six percent had a decrease greater than [0m[1;31m0.5[0m[31m [0m
[31mmEq/L. In the same study, patients treated with lisinopril plus a thiazide diuretic showed essentially no change in serum potassium. [0m[1;31m([0m[31mSee PRECAUTIONS .[0m[1;31m)[0m[31m ACE is identical to kininase, an enzyme that [0m
[31mdegrades bradykinin. Whether increased levels of bradykinin, a potent vasodepressor peptide, play a role in the therapeutic effects of lisinopril remains to be elucidated. While the mechanism through [0m
[31mwhich lisinopril lowers blood pressure is believed to be primarily suppression of the renin-angiotensin-aldosterone system, lisinopril is antihypertensive even in patients with low-renin hypertension.[0m
[31mLISINOPRIL: clinical_pharmacology: Although lisinopril was antihypertensive in all races studied, Black hypertensive patients [0m[1;31m([0m[31musually a low-renin hypertensive population[0m[1;31m)[0m[31m had a smaller average [0m
[31mresponse to lisinopril monotherapy than non-Black patients. Pharmacokinetics and Metabolism Following oral administration of lisinopril, peak serum concentrations occur within about [0m[1;31m7[0m[31m hours. Declining[0m
[31mserum concentrations exhibit a prolonged terminal phase which does not contribute to drug accumulation. This terminal phase probably represents saturable binding to ACE and is not proportional to [0m
[31mdose. Lisinopril does not appear to be bound to other serum proteins. Lisinopril does not undergo metabolism and is excreted unchanged entirely in the urine. Based on urinary recovery, the mean extent[0m
[31mof absorption of lisinopril is approximately [0m[1;31m25[0m[31m percent, with large intersubject variability [0m[1;31m([0m[1;31m6[0m[31m% to [0m[1;31m60[0m[31m%[0m[1;31m)[0m[31m at all doses tested [0m[1;31m([0m[1;31m5[0m[31m mg to [0m[1;31m80[0m[31m mg[0m[1;31m)[0m[31m. LISINOPRIL: clinical_pharmacology: Lisinopril absorption [0m
[31mis not influenced by the presence of food in the gastrointestinal tract. Upon multiple dosing, lisinopril exhibits an effective half-life of accumulation of [0m[1;31m12[0m[31m hours. Impaired renal function decreases[0m
[31melimination of lisinopril, which is excreted principally through the kidneys, but this decrease becomes clinically important only when the glomerular filtration rate is below [0m[1;31m30[0m[31m mL/min. Above this [0m
[31mglomerular filtration rate, the elimination half-life is little changed. With greater impairment, however, peak and trough lisinopril levels increase, time to peak concentration increases and time to [0m
[31mattain steady state is prolonged. Older patients, on average, have [0m[1;31m([0m[31mapproximately doubled[0m[1;31m)[0m[31m higher blood levels and area under the plasma concentration time curve [0m[1;31m([0m[31mAUC[0m[1;31m)[0m[31m than younger patients. [0m[1;31m([0m[31mSee [0m
[31mDOSAGE AND ADMINISTRATION [0m[1;31m)[0m[31m Lisinopril can be removed by hemodialysis. Studies in rats indicate that lisinopril crosses the blood-brain barrier poorly. LISINOPRIL: clinical_pharmacology: Multiple [0m
[31mdoses of lisinopril in rats do not result in accumulation in any tissues. However, milk of lactating rats contains radioactivity following administration of [0m[1;31m14[0m[31m C lisinopril. By whole body [0m
[31mautoradiography, radioactivity was found in the placenta following administration of labeled drug to pregnant rats, but none was found in the fetuses. Pharmacodynamics Administration of lisinopril to [0m
[31mpatients with hypertension results in a reduction of supine and standing blood pressure to about the same extent with no compensatory tachycardia. Symptomatic postural hypotension is usually not [0m
[31mobserved although it can occur and should be anticipated in volume and/or salt-depleted patients. [0m[1;31m([0m[31mSee WARNINGS .[0m[1;31m)[0m[31m In most patients studied, onset of antihypertensive activity was seen at one hour [0m
[31mafter oral administration of an individual dose of lisinopril, with peak reduction of blood pressure achieved by six hours. LISINOPRIL: clinical_pharmacology: In some patients achievement of optimal [0m
[31mblood pressure reduction may require two to four weeks of therapy. At recommended single daily doses, antihypertensive effects have been maintained for at least [0m[1;31m24[0m[31m hours, after dosing, although the [0m
[31meffect at [0m[1;31m24[0m[31m hours was substantially smaller than the effect six hours after dosing. The antihypertensive effects of lisinopril have continued during long-term therapy. Abrupt withdrawal of lisinopril[0m
[31mhas not been associated with a rapid increase in blood pressure; nor with a significant overshoot of pretreatment blood pressure. In hemodynamic studies in patients with essential hypertension, blood [0m
[31mpressure reduction was accompanied by a reduction in peripheral arterial resistance with little or no change in cardiac output and in heart rate. In a study in nine hypertensive patients, following [0m
[31madministration of lisinopril, there was an increase in mean renal blood flow that was not significant.         [0m
[31mSOURCE:LISINOPRIL label[0m


[31mCONTENT: LISINOPRIL: warnings: Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the [0m
[31mrenin-angiotensin system from other antihypertensive agents. Appropriate management of maternal hypertension during pregnancy is important to optimize outcomes for both mother and fetus. In the [0m
[31munusual case that there is no appropriate alternative therapy to drugs affecting the renin-angiotensin system for a particular patient, apprise the mother of the potential risk to the fetus. Perform [0m
[31mserial ultrasound examinations to assess the intra-amniotic environment. If oligohydramnios is observed, discontinue lisinopril and hydrochlorothiazide tablets, unless it is considered lifesaving for [0m
[31mthe mother. Fetal testing may be appropriate, based on the week of pregnancy. Patients and physicians should be aware, however, that oligohydramnios may not appear until after the fetus has sustained [0m
[31mirreversible injury. LISINOPRIL: warnings: Closely observe infants with histories of in utero exposure to lisinopril and hydrochlorothiazide tablets for hypotension, oliguria, and hyperkalemia [0m[1;31m([0m[31m See [0m
[31mPRECAUTIONS, Pediatric Use [0m[1;31m)[0m[31m. Lisinopril-Hydrochlorothiazide Teratogenicity studies were conducted in mice and rats with up to [0m[1;31m90[0m[31m mg/kg/day of lisinopril in combination with [0m[1;31m10[0m[31m mg/kg/day of [0m
[31mhydrochlorothiazide. This dose of lisinopril is [0m[1;31m5[0m[31m times [0m[1;31m([0m[31min mice[0m[1;31m)[0m[31m and [0m[1;31m10[0m[31m times [0m[1;31m([0m[31min rats[0m[1;31m)[0m[31m the maximum recommended human daily dose [0m[1;31m([0m[31mMRHDD[0m[1;31m)[0m[31m when compared on a body surface area basis [0m[1;31m([0m[31mmg/m [0m[1;31m2[0m[31m [0m[1;31m)[0m[31m; the dose[0m
[31mof hydrochlorothiazide is [0m[1;31m0.9[0m[31m times [0m[1;31m([0m[31min mice[0m[1;31m)[0m[31m and [0m[1;31m1.8[0m[31m times [0m[1;31m([0m[31min rats[0m[1;31m)[0m[31m the MRHDD. Maternal or fetotoxic effects were not seen in mice with the combination. LISINOPRIL: warnings: In rats decreased [0m
[31mmaternal weight gain and decreased fetal weight occurred down to [0m[1;31m3[0m[31m/[0m[1;31m10[0m[31m mg/kg/day [0m[1;31m([0m[31mthe lowest dose tested[0m[1;31m)[0m[31m. Associated with the decreased fetal weight was a delay in fetal ossification. The decreased [0m
[31mfetal weight and delay in fetal ossification were not seen in saline-supplemented animals given [0m[1;31m90[0m[31m/[0m[1;31m10[0m[31m mg/kg/day. No teratogenic effects of lisinopril were seen in studies of pregnant mice, rats, and [0m
[31mrabbits. On a body surface area basis, the doses used were up [0m[1;31m55[0m[31m times, [0m[1;31m33[0m[31m times, and [0m[1;31m0.15[0m[31m times, respectively, the MRHDD. Hydrochlorothiazide Studies in which hydrochlorothiazide was orally [0m
[31madministered to pregnant mice and rats during their respective periods of major organogenesis at doses up to [0m[1;31m3000[0m[31m and [0m[1;31m1000[0m[31m mg/kg/day, respectively, provided no evidence of harm to the fetus. These [0m
[31mdoses are more than [0m[1;31m150[0m[31m times the MRHDD on a body surface area basis. LISINOPRIL: warnings: Thiazides cross the placental barrier and appear in cord blood. There is a risk of fetal or neonatal [0m
[31mjaundice, thrombocytopenia and possibly other adverse reactions that have occurred in adults.         [0m
[31mSOURCE:LISINOPRIL label[0m


[31mCONTENT: LISINOPRIL: openfda: pharm_class_pe         [0m
[31mSOURCE:LISINOPRIL label[0m


[31mCONTENT: LISINOPRIL: openfda: pharm_class_cs         [0m
[31mSOURCE:LISINOPRIL label[0m


[31mCONTENT: LISINOPRIL: openfda: spl_id         [0m
[31mSOURCE:LISINOPRIL label[0m


[31mCONTENT: LISINOPRIL: clinical_pharmacology: CLINICAL PHARMACOLOGY Lisinopril-Hydrochlorothiazide As a result of its diuretic effects, hydrochlorothiazide increases plasma renin activity, increases [0m
[31maldosterone secretion, and decreases serum potassium. Administration of lisinopril blocks the renin-angiotensin aldosterone axis and tends to reverse the potassium loss associated with the diuretic. [0m
[31mIn clinical studies, the extent of blood pressure reduction seen with the combination of lisinopril and hydrochlorothiazide was approximately additive. The lisinopril and hydrochlorothiazide tablets [0m
[1;31m10[0m[31m-[0m[1;31m12.5[0m[31m combination worked equally well in Black and Caucasian patients. The lisinopril and hydrochlorothiazide tablets [0m[1;31m20[0m[31m-[0m[1;31m12.5[0m[31m and lisinopril and hydrochlorothiazide tablets [0m[1;31m20[0m[31m-[0m[1;31m25[0m[31m combinations [0m
[31mappeared somewhat less effective in Black patients, but relatively few Black patients were studied. LISINOPRIL: clinical_pharmacology: In most patients, the antihypertensive effect of lisinopril and [0m
[31mhydrochlorothiazide tablets was sustained for at least [0m[1;31m24[0m[31m hours. In a randomized, controlled comparison, the mean antihypertensive effects of lisinopril and hydrochlorothiazide tablets [0m[1;31m20[0m[31m-[0m[1;31m12.5[0m[31m and [0m
[31mlisinopril and hydrochlorothiazide tablets [0m[1;31m20[0m[31m-[0m[1;31m25[0m[31m were similar, suggesting that many patients who respond adequately to the latter combination may be controlled with lisinopril and hydrochlorothiazide [0m
[31mtablets [0m[1;31m20[0m[31m-[0m[1;31m12.5[0m[31m. [0m[1;31m([0m[31mSee DOSAGE AND ADMINISTRATION .[0m[1;31m)[0m[31m Concomitant administration of lisinopril and hydrochlorothiazide has little or no effect on the bioavailability of either drug. The combination [0m
[31mtablet is bioequivalent to concomitant administration of the separate entities. LISINOPRIL: clinical_pharmacology: Lisinopril Mechanism of Action Lisinopril inhibits angiotensin-converting enzyme [0m
[1;31m([0m[31mACE[0m[1;31m)[0m[31m in human subjects and animals. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. Angiotensin II also stimulates [0m
[31maldosterone secretion by the adrenal cortex. Inhibition of ACE results in decreased plasma angiotensin II which leads to decreased vasopressor activity and to decreased aldosterone secretion. The [0m
[31mlatter decrease may result in a small increase of serum potassium. Removal of angiotensin II negative feedback on renin secretion leads to increased plasma renin activity. In hypertensive patients [0m
[31mwith normal renal function treated with lisinopril alone for up to [0m[1;31m24[0m[31m weeks, the mean increase in serum potassium was less than [0m[1;31m0[0m[31m.         [0m
[31mSOURCE:LISINOPRIL label[0m


[31mCONTENT: LISINOPRIL: pharmacokinetics: Pharmacokinetics and Metabolism Following oral administration of lisinopril, peak serum concentrations occur within about [0m[1;31m7[0m[31m hours. Declining serum concentrations[0m
[31mexhibit a prolonged terminal phase which does not contribute to drug accumulation. This terminal phase probably represents saturable binding to ACE and is not proportional to dose. Lisinopril does not[0m
[31mappear to be bound to other serum proteins. Lisinopril does not undergo metabolism and is excreted unchanged entirely in the urine. Based on urinary recovery, the mean extent of absorption of [0m
[31mlisinopril is approximately [0m[1;31m25[0m[31m percent, with large intersubject variability [0m[1;31m([0m[1;31m6[0m[31m% to [0m[1;31m60[0m[31m%[0m[1;31m)[0m[31m at all doses tested [0m[1;31m([0m[1;31m5[0m[31m mg to [0m[1;31m80[0m[31m mg[0m[1;31m)[0m[31m. Lisinopril absorption is not influenced by the presence of food in the [0m
[31mgastrointestinal tract. Upon multiple dosing, lisinopril exhibits an effective half-life of accumulation of [0m[1;31m12[0m[31m hours. LISINOPRIL: pharmacokinetics: Impaired renal function decreases elimination of [0m
[31mlisinopril, which is excreted principally through the kidneys, but this decrease becomes clinically important only when the glomerular filtration rate is below [0m[1;31m30[0m[31m mL/min. Above this glomerular [0m
[31mfiltration rate, the elimination half-life is little changed. With greater impairment, however, peak and trough lisinopril levels increase, time to peak concentration increases and time to attain [0m
[31msteady state is prolonged. Older patients, on average, have [0m[1;31m([0m[31mapproximately doubled[0m[1;31m)[0m[31m higher blood levels and area under the plasma concentration time curve [0m[1;31m([0m[31mAUC[0m[1;31m)[0m[31m than younger patients. [0m[1;31m([0m[31mSee DOSAGE AND [0m
[31mADMINISTRATION [0m[1;31m)[0m[31m Lisinopril can be removed by hemodialysis. Studies in rats indicate that lisinopril crosses the blood-brain barrier poorly. Multiple doses of lisinopril in rats do not result in [0m
[31maccumulation in any tissues. However, milk of lactating rats contains radioactivity following administration of [0m[1;31m14[0m[31m C lisinopril. LISINOPRIL: pharmacokinetics: By whole body autoradiography, [0m
[31mradioactivity was found in the placenta following administration of labeled drug to pregnant rats, but none was found in the fetuses.         [0m
[31mSOURCE:LISINOPRIL label[0m


[31mCONTENT: LISINOPRIL: adverse_reactions: [0m[1;31m0[0m[31m Body as a Whole: Chest pain, abdominal pain, syncope, chest discomfort, fever, trauma, virus infection. Cardiovascular: Palpitation, orthostatic hypotension. [0m
[31mDigestive: Gastrointestinal cramps, dry mouth, constipation, heartburn. Musculoskeletal: Back pain, shoulder pain, knee pain, back strain, myalgia, foot pain. Nervous/Psychiatric: Decreased libido, [0m
[31mvertigo, depression, somnolence. Respiratory: Common cold, nasal congestion, influenza, bronchitis, pharyngeal pain, dyspnea, pulmonary congestion, chronic sinusitis, allergic rhinitis, pharyngeal [0m
[31mdiscomfort. Skin: Flushing, pruritus, skin inflammation, diaphoresis. Special Senses: Blurred vision, tinnitus, otalgia. Urogenital: Urinary tract infection. LISINOPRIL: adverse_reactions: Angioedema:[0m
[31mAngioedema has been reported in patients receiving PRINZIDE, with an incidence higher in Black than in non-Black patients. Angioedema associated with laryngeal edema may be fatal. If angioedema of the[0m
[31mface, extremities, lips, tongue, glottis and/or larynx occurs, treatment with PRINZIDE should be discontinued and appropriate therapy instituted immediately. In rare cases, intestinal angioedema has [0m
[31mbeen reported with angiotensin converting enzyme inhibitors including lisinopril. [0m[1;31m([0m[31mSee WARNINGS [0m[1;31m)[0m[31m. Hypotension: In clinical trials, adverse effects relating to hypotension occurred as follows: [0m
[31mhypotension [0m[1;31m([0m[1;31m1.4[0m[31m percent[0m[1;31m)[0m[31m, orthostatic hypotension [0m[1;31m([0m[1;31m0.5[0m[31m percent[0m[1;31m)[0m[31m, other orthostatic effects [0m[1;31m([0m[1;31m3.2[0m[31m percent[0m[1;31m)[0m[31m. In addition syncope occurred in [0m[1;31m0.8[0m[31m percent of patients [0m[1;31m([0m[31mSee WARNINGS [0m[1;31m)[0m[31m. LISINOPRIL: [0m
[31madverse_reactions: Cough: See PRECAUTIONS - Cough . Clinical Laboratory Test Findings Serum Electrolytes: [0m[1;31m([0m[31mSee PRECAUTIONS [0m[1;31m)[0m[31m. Creatinine, Blood Urea Nitrogen: Minor reversible increases in blood urea [0m
[31mnitrogen and serum creatinine were observed in patients with essential hypertension treated with lisinopril and hydrochlorothiazide tablets. More marked increases have also been reported and were more[0m
[31mlikely to occur in patients with renal artery stenosis [0m[1;31m([0m[31mSee PRECAUTIONS [0m[1;31m)[0m[31m. Serum Uric Acid, Glucose, Magnesium, Cholesterol, Triglycerides and Calcium: [0m[1;31m([0m[31mSee PRECAUTIONS [0m[1;31m)[0m[31m. Hemoglobin and Hematocrit: [0m
[31mSmall decreases in hemoglobin and hematocrit [0m[1;31m([0m[31mmean decreases of approximately [0m[1;31m0.5[0m[31m g% and [0m[1;31m1.5[0m[31m vol%, respectively[0m[1;31m)[0m[31m occurred frequently in hypertensive patients treated with lisinopril and [0m
[31mhydrochlorothiazide tablets but were rarely of clinical importance unless another cause of anemia coexisted. LISINOPRIL: adverse_reactions: In clinical trials, [0m[1;31m0.4[0m[31m% of patients discontinued therapy [0m
[31mdue to anemia. Liver Function Tests: Rarely, elevations of liver enzymes and/or serum bilirubin have occurred. [0m[1;31m([0m[31mSee WARNINGS, Hepatic Failure [0m[1;31m)[0m[31m. Other adverse reactions that have been reported with [0m
[31mthe individual components are listed below: Lisinopril - In clinical trials adverse reactions which occurred with lisinopril were also seen with lisinopril and hydrochlorothiazide tablets. LISINOPRIL:[0m
[31madverse_reactions: In addition, and since lisinopril has been marketed, the following adverse reactions have been reported with lisinopril and should be considered potential adverse reactions for [0m
[31mlisinopril and hydrochlorothiazide tablets: Body as a Whole: Anaphylactoid reactions [0m[1;31m([0m[31msee WARNINGS, Anaphylactoid and Possibly Related Reactions [0m[1;31m)[0m[31m, malaise, edema, facial edema, pain, pelvic pain, [0m
[31mflank pain, chills; Cardiovascular: Cardiac arrest, myocardial infarction or cerebrovascular accident, possibly secondary to excessive hypotension in high risk patients [0m[1;31m([0m[31msee WARNINGS, Hypotension [0m[1;31m)[0m[31m, [0m
[31mpulmonary embolism and infarction, worsening of heart failure, arrhythmias [0m[1;31m([0m[31mincluding tachycardia, ventricular tachycardia, atrial tachycardia, atrial fibrillation, bradycardia, and premature [0m
[31mventricular contractions[0m[1;31m)[0m[31m, angina pectoris, transient ischemic attacks LISINOPRIL: adverse_reactions: , paroxysmal nocturnal dyspnea, decreased blood pressure, peripheral edema, vasculitis; Digestive:[0m
[31mPancreatitis, hepatitis [0m[1;31m([0m[31mhepatocellular or cholestatic jaundice[0m[1;31m)[0m[31m [0m[1;31m([0m[31msee WARNINGS, Hepatic Failure [0m[1;31m)[0m[31m, gastritis, anorexia, flatulence, increased salivation; Endocrine: Diabetes mellitus, syndrome of [0m
[31minappropriate antidiuretic hormone secretion [0m[1;31m([0m[31mSIADH[0m[1;31m)[0m[31m; Hematologic: Rare cases of neutropenia, thrombocytopenia, and bone marrow depression have been reported. LISINOPRIL: adverse_reactions: Hemolytic [0m
[31manemia has been reported; a causal relationship to lisinopril cannot be excluded; Metabolic: Gout, weight loss, dehydration, fluid overload, weight gain; Musculoskeletal: Arthritis, arthralgia, neck [0m
[31mpain, hip pain, joint pain, leg pain, arm pain, lumbago; Nervous System/Psychiatric: Ataxia, memory impairment, tremor, insomnia, stroke, nervousness, confusion, peripheral neuropathy [0m[1;31m([0m[31me.g. [0m
[31mLISINOPRIL: adverse_reactions: paresthesia, dysesthesia[0m[1;31m)[0m[31m, spasm, hypersomnia, irritability, mood alterations [0m[1;31m([0m[31mincluding depressive symptoms[0m[1;31m)[0m[31m; hallucinations ; Respiratory: Malignant lung neoplasms, [0m
[31mhemoptysis, pulmonary edema, pulmonary infiltrates, eosinophilic pneumonitis, bronchospasm, asthma, pleural effusion, pneumonia, wheezing, orthopnea, painful respiration, epistaxis, laryngitis, [0m
[31msinusitis, pharyngitis, rhinitis, rhinorrhea, chest sound abnormalities; Skin: Urticaria, alopecia, herpes zoster, photosensitivity, skin lesions, skin infections, pemphigus, erythema, psoriasis.     [0m
[31mSOURCE:LISINOPRIL label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m
[32mANSWER: The provided extracts from the LISINOPRIL label do not specifically mention an increase or decrease in the risk of bleeding as an effect of the drug. The adverse reactions section lists [0m
[32mvarious potential side effects, but bleeding is not explicitly mentioned among them.[0m

[32mSOURCE: LISINOPRIL label[0m
[32mEXTRACT_START_END: LISINOPRIL: adverse_reactions: [0m[1;32m0[0m[32m Body as a Whole: Chest pain, abdominal pain, syncope[0m[32m...[0m[32m erythema, psoriasis.[0m
*[1m([0morchestrator-bleeding-LISINOPRIL[1m)[0m [37m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mANSWER: The provided extracts from the LISINOPRIL label do not specifically [0m
[34mmention an increase or decrease in the risk of bleeding as an effect of the drug. The adverse reactions section lists various potential side effects, but bleeding is not explicitly mentioned among [0m
[34mthem.[0m

[34mSOURCE: LISINOPRIL label[0m
[34mEXTRACT_START_END: LISINOPRIL: adverse_reactions: [0m[1;34m0[0m[34m Body as a Whole: Chest pain, abdominal pain, syncope[0m[34m...[0m[34m erythema, psoriasis.[0m
 [1m([0morchestrator-bleeding-LISINOPRIL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-bleeding-LISINOPRIL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-bleeding-LISINOPRIL[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does LISINOPRIL increase or decrease the risk of bleeding?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I asked FDAHandler if LISINOPRIL increases or decreases the risk of bleeding."[0m[32m,[0m
[32m      [0m[32m"FDAHandler responded that the LISINOPRIL label does not specifically mention an increase or decrease in the risk of bleeding. The adverse reactions section lists various potential side effects,[0m
[32mbut bleeding is not explicitly mentioned among them."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"The FDA label for LISINOPRIL does not specify whether it increases or decreases the risk of bleeding."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-bleeding-LISINOPRIL[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-bleeding-LISINOPRIL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-bleeding-LISINOPRIL[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-bleeding-LISINOPRIL[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does LISINOPRIL increase or decrease the risk of bleeding?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I asked FDAHandler if LISINOPRIL increases or decreases the risk of bleeding."[0m[34m,[0m
[34m      [0m[34m"FDAHandler responded that the LISINOPRIL label does not specifically mention an increase or decrease in the risk of bleeding. The adverse reactions section lists various potential side effects,[0m
[34mbut bleeding is not explicitly mentioned among them."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"The FDA label for LISINOPRIL does not specify whether it increases or decreases the risk of bleeding."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does LISINOPRIL increase or decrease the risk of bleeding?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I asked FDAHandler if LISINOPRIL increases or decreases the risk of bleeding.[0m
[1;31m2[0m[31m. FDAHandler responded that the LISINOPRIL label does not specifically mention an increase or decrease in the risk of bleeding. The adverse reactions section lists various potential side effects, but[0m
[31mbleeding is not explicitly mentioned among them.[0m
[31m        -----[0m
[31m        Final answer: The FDA label for LISINOPRIL does not specify whether it increases or decreases the risk of bleeding.[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m""[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-bleeding-LISINOPRIL[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m""[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-bleeding-LISINOPRIL[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mYour reasoning is valid, no feedback was provided.[0m
 [1m([0morchestrator-bleeding-LISINOPRIL[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-bleeding-LISINOPRIL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-bleeding-LISINOPRIL[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m The FDA label for LISINOPRIL does not specify whether it increases or [0m
[32mdecreases the risk of bleeding.[0m
